IRIS Institutional Research Information System - OPENBS Open Archive UniBS

ADAMO, MARIANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.214
AS - Asia 8.333
EU - Europa 3.973
SA - Sud America 1.958
Continente sconosciuto - Info sul continente non disponibili 287
AF - Africa 209
OC - Oceania 14
AN - Antartide 1
Totale 23.989
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.871
SG - Singapore 3.025
CN - Cina 1.949
BR - Brasile 1.649
HK - Hong Kong 1.284
IT - Italia 1.004
VN - Vietnam 628
DE - Germania 593
BD - Bangladesh 467
RU - Federazione Russa 380
GB - Regno Unito 366
FR - Francia 363
FI - Finlandia 322
TR - Turchia 305
UA - Ucraina 205
IN - India 200
IE - Irlanda 170
CA - Canada 165
AR - Argentina 117
NL - Olanda 88
MX - Messico 85
PL - Polonia 81
IQ - Iraq 76
ZA - Sudafrica 76
JP - Giappone 68
AT - Austria 65
SE - Svezia 65
CZ - Repubblica Ceca 60
ES - Italia 57
ID - Indonesia 51
SA - Arabia Saudita 48
EC - Ecuador 47
PK - Pakistan 40
VE - Venezuela 38
CO - Colombia 32
MA - Marocco 32
BE - Belgio 26
UZ - Uzbekistan 26
PY - Paraguay 24
CL - Cile 22
KE - Kenya 22
TN - Tunisia 22
JM - Giamaica 18
EG - Egitto 17
AE - Emirati Arabi Uniti 16
PH - Filippine 16
CH - Svizzera 15
MD - Moldavia 15
CR - Costa Rica 13
JO - Giordania 13
NP - Nepal 13
PE - Perù 13
SC - Seychelles 13
TT - Trinidad e Tobago 13
IL - Israele 12
LT - Lituania 12
BG - Bulgaria 11
HN - Honduras 11
AU - Australia 10
MY - Malesia 10
UY - Uruguay 10
LV - Lettonia 9
AZ - Azerbaigian 8
GR - Grecia 8
KR - Corea 8
KZ - Kazakistan 8
DZ - Algeria 7
HU - Ungheria 7
IR - Iran 7
PA - Panama 7
PT - Portogallo 7
TH - Thailandia 7
LB - Libano 6
PS - Palestinian Territory 6
RO - Romania 6
RS - Serbia 6
SV - El Salvador 6
AL - Albania 5
BB - Barbados 5
BO - Bolivia 5
ET - Etiopia 5
GT - Guatemala 5
TW - Taiwan 5
CY - Cipro 4
EU - Europa 4
NG - Nigeria 4
NO - Norvegia 4
OM - Oman 4
AM - Armenia 3
BA - Bosnia-Erzegovina 3
BY - Bielorussia 3
DO - Repubblica Dominicana 3
KG - Kirghizistan 3
KW - Kuwait 3
LA - Repubblica Popolare Democratica del Laos 3
NI - Nicaragua 3
NZ - Nuova Zelanda 3
PR - Porto Rico 3
SK - Slovacchia (Repubblica Slovacca) 3
AO - Angola 2
Totale 23.663
Salva come PNG Salva come JPEG
Città #
Singapore 1.464
Hong Kong 1.278
Ashburn 940
San Jose 633
Beijing 595
The Dalles 546
Chandler 449
New York 400
Fairfield 365
Los Angeles 354
Lauterbourg 271
Columbus 241
Istanbul 241
Princeton 240
Ho Chi Minh City 224
Helsinki 222
Houston 198
Council Bluffs 189
Seattle 172
Dublin 170
Woodbridge 167
Milan 158
São Paulo 151
Dallas 150
Munich 146
Wilmington 143
Buffalo 141
Moscow 138
Cambridge 131
Redondo Beach 125
Jacksonville 121
Hanoi 119
Chicago 110
Santa Clara 107
Shanghai 98
Romola 89
Frankfurt am Main 82
Orem 75
San Francisco 75
Ann Arbor 73
London 69
Rome 68
Warsaw 64
Atlanta 58
Tokyo 58
Montreal 56
Brooklyn 51
Nuremberg 51
Brescia 49
Chennai 46
Denver 46
Lappeenranta 46
Rio de Janeiro 45
Turku 45
Brno 44
Johannesburg 43
Phoenix 43
Poplar 40
Toronto 39
Boardman 38
Des Moines 38
Boston 36
Guangzhou 36
Stockholm 35
Belo Horizonte 32
San Diego 32
Brasília 31
Haiphong 30
Amsterdam 29
Charlotte 29
Düsseldorf 29
Vienna 29
Hangzhou 27
Pune 26
Washington 26
Brussels 25
Curitiba 24
Da Nang 23
Mexico City 23
Salt Lake City 23
Kyiv 22
Salvador 22
Ankara 21
Changsha 21
Mumbai 21
Naples 21
Porto Alegre 21
Tashkent 21
Manchester 20
Riyadh 20
Baghdad 19
Brindisi 19
Buenos Aires 19
Nairobi 19
Biên Hòa 18
Dhaka 18
Erbil 18
Nanjing 17
Quito 17
Tianjin 17
Totale 13.564
Salva come PNG Salva come JPEG
Nome #
May 2020 at a glance: ischaemic heart failure and sex-related differences 241
Percutaneous edge-to-edge mitral valve repair for the treatment of acute mitral regurgitation complicating myocardial infarction: A single centre experience 201
Left ventricular reverse remodelling predicts long-term outcomes in patients with functional mitral regurgitation undergoing MitraClip therapy: results from a multicentre registry 196
Mitraclip therapy in patients with functional mitral regurgitation and missing leaflet coaptation: is it still an exclusion criterion? 193
Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy 189
Self-expanding transcatheter aortic valve implantation for degenerated small Mitroflow bioprosthesis: Early and midterm outcomes 187
2024 update in heart failure 183
Effectiveness of MitraClip therapy in patients with refractory heart failure 182
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 170
EkoSonic Endovascular System for patients with acute pulmonary embolism and contraindication to systemic fibrinolysis 161
Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE-HF2 trial and comparison to COAPT and MITRA-FR trials 156
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC 154
August 2020 at a glance: focus on neurohormonal antagonists and electrolytes 153
Interaction between severe chronic kidney disease and acute kidney injury in predicting mortality after transcatheter aortic valve implantation: Insights from the Italian Clinical Service Project 129
Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19) 121
The Mayo ATTR-CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis 120
Prognostic value of right ventricle to pulmonary artery coupling in transcatheter aortic valve implantation recipients 118
COAPT-Like Profile Predicts Long-Term Outcomes in Patients With Secondary Mitral Regurgitation Undergoing MitraClip Implantation 118
Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis 117
Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care 117
Role of nutrition in heart failure patients 117
Biologically active adrenomedullin as a marker for residual congestion and early rehospitalization in patients hospitalized for acute heart failure: Data from STRONG-HF 116
Transcatheter Mitral Valve Repair in Cardiogenic Shock and Mitral Regurgitation: A Patient-Level, Multicenter Analysis 113
Highlights in valvular heart diseases 113
April 2020 at a glance: epidemiology, prevention, and biomarkers 111
Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention? A Pre-Specified Analysis from the ZEUS Trial 111
Role of different vascular approaches on transcatheter aortic valve implantation outcome: a single-center study. 110
COVID 19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease 110
Changes in Right Ventricular-to-Pulmonary Artery Coupling After Transcatheter Edge-to-Edge Repair in Secondary Mitral Regurgitation 109
TRIVALVE Score: A Risk Score for Mortality/Hospitalization Prediction in Patients Undergoing Transcatheter Tricuspid Valve Intervention 109
September 2019 at a glance: focus on devices 109
Highlights in heart failure 109
Machine learning for prediction of in-hospital mortality in coronavirus disease 2019 patients: results from an Italian multicenter study 108
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC 108
January 2020 at a glance: translational medicine, predictors of outcome and treatments 108
Trans-axillary versus trans - aortic approach for transcatheter aortic valve implantation with corevalve revalving system: insights from multicenter experience 108
ACE2 down-regulation may contribute to the increased thrombotic risk in COVID-19 108
[Italian Society of Cardiology-Italian Society of Nephrology Consensus document: The cardio-renal interaction in the prevention and treatment of cardiovascular diseases - Part II: From preventive strategies to treatment of patients with cardio-renal damage] 107
Impact of disproportionate secondary mitral regurgitation in patients undergoing edge-to-edge percutaneous mitral valve repair 107
Prediction of mortality and heart failure hospitalisations in patients undergoing M-TEER: external validation of the COAPT risk score 106
Life-saving transcatheter aortic valve implantation for acute severe aortic regurgitation due to rheumatoid arthritis and complicated by cardiogenic shock 106
MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 1-year outcomes from the International MitraBridge Registry 106
Hepatic T1-time, cardiac structure and function and cardiovascular outcomes in patients with dilated cardiomyopathy 106
[RESHAPE-HF2: new evidence and clinical implications] 105
[Italian Society of Cardiology-Italian Society of Nephrology Consensus document: The cardio-renal interaction in the prevention and treatment of cardiovascular diseases - Part I: From cardiovascular risk factors to the mechanisms of cardio-renal syndrome] 104
Residual tricuspid regurgitation after tricuspid transcatheter edge-to-edge repair: Insights into the EuroTR registry 104
Acute heart failure and valvular heart disease: A scientific statement of the Heart Failure Association, the Association for Acute CardioVascular Care and the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology 104
Prognostic Value of Pre-operative Atrial Fibrillation in Patients With Secondary Mitral Regurgitation Undergoing MitraClip Implantation 104
[Advances in heart failure treatment: a summary of 50 years of evolution] 103
December 2019 at a glance: economic burden, co-morbidities, and prognosis 103
Atrial fibrillation in the COVID-19 era: Simple bystander or marker of increased risk? 103
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC 102
Congestion in Patients with Advanced Heart Failure: Assessment and Treatment 102
Prognostic Impact of Heart Failure History in Patients with Secondary Mitral Regurgitation Treated by MitraClip 102
[2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure] 101
2-year outcomes of MitraClip as a bridge to heart transplantation: The international MitraBridge registry 101
Characteristics and outcomes of patients with atrial versus ventricular secondary tricuspid regurgitation undergoing tricuspid transcatheter edge-to-edge repair - Results from the TriValve registry 100
Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology 100
Transcatheter therapies for tricuspid valve regurgitation 100
Sex differences in pulmonary arterial hypertension: Insights from the FOCUS-PAH registry 99
A Score to Assess Mortality After Percutaneous Mitral Valve Repair 98
Titration of Medications After Acute Heart Failure Is Safe, Tolerated, and Effective Regardless of Risk 98
Long-Term Outcomes After Edge-to-Edge Repair of Secondary Mitral Regurgitation: 5-Year Results From the EuroSMR Registry 97
Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis 97
Quality of life in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation: tools and evidence 97
Percutaneous valve repair of functional mitral regurgitation: aiming at optimal and durable results 97
Impact of COVID-2019 outbreak on prevalence, clinical presentation and outcomes of ST-elevation myocardial infarction 96
[Sodium-glucose cotransporter 2 inhibitors and heart failure with preserved ejection fraction: the EMPEROR-Preserved and DELIVER studies] 94
Medical therapy of cardiogenic shock: Contemporary use of inotropes and vasopressors 94
Impact on clinical outcomes of right ventricular response to percutaneous correction of secondary mitral regurgitation 94
Derivation and Validation of a Clinical Risk Score for COAPT-Ineligible Patients Who Underwent Transcatheter Edge-to-Edge Repair 94
Transcatheter Edge-to-Edge Repair in COAPT-Ineligible Patients: Incidence and Predictors of 2-Year Good Outcome 94
Right heart failure and mortality in patients undergoing transcatheter tricuspid valve interventions 93
Treatment of functional mitral regurgitation in chronic heart failure: can we get a 'proof of concept' from the MITRA-FR and COAPT trials? 93
Clinical management and therapeutic optimization of patients with heart failure with reduced ejection fraction and low blood pressure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC 92
Telemedicine for the treatment of heart failure: new opportunities after COVID-19 92
Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 pathogenic variant 92
COVID-19 and Heart Failure: From Epidemiology During the Pandemic to Myocardial Injury, Myocarditis, and Heart Failure Sequelae 91
Staging Heart Failure Patients With Secondary Mitral Regurgitation Undergoing Transcatheter Edge-to-Edge Repair 91
April 2022 at a glance: focus on prevention, acute heart failure and heart failure with preserved ejection fraction 90
[Transcatheter devices for chronic heart failure: state of the art] 90
2023 focused update of the 2021 ESC heart failure guidelines: Key messages for clinical practice 90
Impact of Transcatheter Edge-to-Edge Mitral Valve Repair on Guideline-Directed Medical Therapy Uptitration 89
Prognostic value of right ventricular longitudinal strain in patients with secondary mitral regurgitation undergoing transcatheter edge-to-edge mitral valve repair 88
Impact of malnutrition in patients with severe heart failure 88
Decongestion and Outcomes in Patients Hospitalized for Acute Heart Failure: Insights From the RELAX-AHF-2 Trial 88
Sodium glucose co-transporter 2 inhibitors and quality of life in patients with heart failure: a comprehensive systematic review and meta-analysis of randomized controlled trials 88
Percutaneous treatment of mitral regurgitation: looking for a final model 88
Sex-related differences in patients with coronavirus disease 2019: results of the Cardio-COVID-Italy multicentre study 88
April 2021 at a glance: focus on systolic function, quality of life and treatment in heart failure 88
Characteristics and outcomes of patients with tricuspid regurgitation and advanced heart failure 87
Prevalence, Characteristics and Prognostic Impact of Aortic Valve Disease in Patients with Heart Failure and Reduced, Mildly Reduced, and Preserved Ejection Fraction: An Analysis of the ESC Heart Failure Long-Term Registry 87
August 2021 at a glance: focus on cardiomyopathies, medical treatment and devices 87
A meta-analysis of MitraClip combined with medical therapy vs. medical therapy alone for treatment of mitral regurgitation in heart failure patients 87
July 2021 at a glance: focus on blood volume distribution, haemodynamics and adherence to therapy 87
Frailty according to the 2019 HFA-ESC definition in patients at risk for advanced heart failure: Insights from the HELP-HF registry 86
Use of MitraClip for mitral valve repair in patients with acute mitral regurgitation following acute myocardial infarction: Effect of cardiogenic shock on outcomes (IREMMI Registry) 85
Cardiac contractility modulation: an effective treatment strategy for heart failure beyond reduced left ventricular ejection fraction? 85
Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure 85
Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT-CHF 85
Totale 11.088
Salva come PNG Salva come JPEG
Categoria #
all - tutte 157.026
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 157.026
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022705 0 102 22 83 21 57 15 76 34 51 42 202
2022/20231.347 150 48 20 115 101 377 10 144 201 19 85 77
2023/20242.078 111 39 174 150 117 243 144 62 502 79 81 376
2024/20255.393 46 47 185 502 506 433 572 304 440 607 1.067 684
2025/202611.764 1.148 1.557 898 1.730 1.062 708 1.359 529 790 939 625 419
2026/2027911 615 296 0 0 0 0 0 0 0 0 0 0
Totale 23.989